Trial Profile
Phase I Study of Regorafenib and Nivolumab in Mismatch Repair (MMR) Proficient Advanced Refractory Colorectal Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 09 Apr 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Regorafenib (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 04 Apr 2024 Planned End Date changed from 26 Feb 2024 to 18 May 2024.
- 07 Feb 2024 Planned End Date changed from 26 Jan 2024 to 26 Feb 2024.
- 19 Jan 2024 Planned End Date changed from 1 Dec 2023 to 26 Jan 2024.